Quarterly Investor Webinar
Released
Released
Announcement PDF
ASX Announcement
29 April 2025
ReNerve Ltd – Quarterly Report Webinar
Wednesday, 7 May 2025 at 11:00am (AEST)
ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”) is pleased to invite shareholders and prospective investors
to an investor webinar, where ReNerve CEO, Dr Julian Chick will provide an update to accompany the recent
Quarterly Report.
Event Details:
ReNerve Limited (ASX:RNV) Investor Webinar
Date/Time:
Wednesday 7 May 2025,
11:00am AEST (9:00am AWST)
Presenter:
Dr Julian Chick, CEO of ReNerve Ltd
Registration:
https://bit.ly/RNV-Q3-FY2025
During the webinar, Dr Chick will provide a Company update for the Quarter ended 31 March 2025, as well as an
overview for the remainder of CY2025.
This will be followed by a brief live Q&A session, where Dr Chick will be answering questions that attendees are
able to submit ahead of time, or using the live Q&A feature on Zoom.
Attendees are invited to submit questions prior to the webinar to info@janemorganmanagement.com.au
This announcement has been approved for release by the Company’s Board of Directors.
For further information and enquiries, please contact:
Dr Julian Chick
CEO
ReNerve Ltd
+61 (0) 417 137 291
Jane Morgan
Investor & Media Relations
Jane Morgan Management
+61 (0) 405 555 618
info@renerve.com.au
jm@janemorganmanagement.com.au
+61 (03) 9482 3940
157 Heidelberg Rd,
Northcote, VIC 3070
www.renerve.com.au
About ReNerve™ Limited
ReNerve Limited (ASX:RNV) is an Australian-based biotechnology company specialising in advanced nerve repair
and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissueengineering products that seek to address significant unmet needs in peripheral nerve damage patients – a critical
gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been
developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable
products for the healthcare market. ReNerve wishes to acknowledge AusIndustry’s Accelerating Commercialisation
program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff™.
2|Page
Share your feedback
Discover